Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.

February 16, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Phathom Pharmaceuticals with a $26 price target.
The reiteration of a Buy rating and maintenance of a $26 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively impact Phathom Pharmaceuticals' stock price in the short term. The specific mention of the price target provides a clear expectation of value, which can influence investor sentiment and trading behavior.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100